Journal: Oncology Letters

Article Title: ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer

doi: 10.3892/ol.2020.11768

Figure Lengend Snippet: ANGPTL4 expression in normal breast (n=40), ADH (n=40), DCIS (n=40) and IDC (n=205) tissues.

Article Snippet: Non-specific binding sites were blocked by incubation with 10% normal goat serum (cat. no. ab7481; Abcam) at room temperature for 20 min. Tissue sections were then incubated with a primary ANGPTL4 polyclonal antibody (dilution, 1:100; cat. no. A01147; Boster Biological Technology) at 37°C for 2 h. All sections were subsequently incubated using the Dako REALTM EnVisionTM Detection System (cat. no. K5007; Dako; Agilent Technologies, Inc.) containing biotinylated anti-rabbit secondary antibodies (dilution, 1:100) for 20 min at 37°C, and peroxidase-labelled streptavidin for 20 min at room temperature (dilution, 1:100).

Techniques: Expressing

Journal: Oncology Letters

Article Title: ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer

doi: 10.3892/ol.2020.11768

Figure Lengend Snippet: The IHC staining of angiopoietin-like 4 expression in normal breast, atypical ductal hyperplasia and ductal carcinoma in situ tissues. Angiopoietin-like 4 in normal breast tissues: (A1) Negative, (A2) positive; in atypical ductal hyperplasia tissues: (B1) Negative, (B2) positive; and in ductal carcinoma in situ tissues: (C1) Negative, (C2) positive. Magnification, x200.

Article Snippet: Non-specific binding sites were blocked by incubation with 10% normal goat serum (cat. no. ab7481; Abcam) at room temperature for 20 min. Tissue sections were then incubated with a primary ANGPTL4 polyclonal antibody (dilution, 1:100; cat. no. A01147; Boster Biological Technology) at 37°C for 2 h. All sections were subsequently incubated using the Dako REALTM EnVisionTM Detection System (cat. no. K5007; Dako; Agilent Technologies, Inc.) containing biotinylated anti-rabbit secondary antibodies (dilution, 1:100) for 20 min at 37°C, and peroxidase-labelled streptavidin for 20 min at room temperature (dilution, 1:100).

Techniques: Immunohistochemistry, Expressing, In Situ

Journal: Oncology Letters

Article Title: ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer

doi: 10.3892/ol.2020.11768

Figure Lengend Snippet: Angiopoietin-like 4 expression in invasive ductal carcinoma. (A1) Negative (magnification, x200); (A2) negative (magnification, x400); (B1) weakly positive (magnification, x200); (B2) weakly positive (magnification, x400); (C1) moderately positive (magnification, x200); (C2) moderately positive (magnification, x400); (D1) strongly positive (magnification, x200); (D2) strongly positive (magnification, x400).

Article Snippet: Non-specific binding sites were blocked by incubation with 10% normal goat serum (cat. no. ab7481; Abcam) at room temperature for 20 min. Tissue sections were then incubated with a primary ANGPTL4 polyclonal antibody (dilution, 1:100; cat. no. A01147; Boster Biological Technology) at 37°C for 2 h. All sections were subsequently incubated using the Dako REALTM EnVisionTM Detection System (cat. no. K5007; Dako; Agilent Technologies, Inc.) containing biotinylated anti-rabbit secondary antibodies (dilution, 1:100) for 20 min at 37°C, and peroxidase-labelled streptavidin for 20 min at room temperature (dilution, 1:100).

Techniques: Expressing

Journal: Oncology Letters

Article Title: ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer

doi: 10.3892/ol.2020.11768

Figure Lengend Snippet: Association between ANGPTL4 expression and clinical parameters in 205 patients with invasive ductal carcinoma.

Article Snippet: Non-specific binding sites were blocked by incubation with 10% normal goat serum (cat. no. ab7481; Abcam) at room temperature for 20 min. Tissue sections were then incubated with a primary ANGPTL4 polyclonal antibody (dilution, 1:100; cat. no. A01147; Boster Biological Technology) at 37°C for 2 h. All sections were subsequently incubated using the Dako REALTM EnVisionTM Detection System (cat. no. K5007; Dako; Agilent Technologies, Inc.) containing biotinylated anti-rabbit secondary antibodies (dilution, 1:100) for 20 min at 37°C, and peroxidase-labelled streptavidin for 20 min at room temperature (dilution, 1:100).

Techniques: Expressing

Journal: Oncology Letters

Article Title: ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer

doi: 10.3892/ol.2020.11768

Figure Lengend Snippet: Survival curves based on ANGPTL4 expression. (A) DFS and (B) OS analysis of ANGPTL4 in breast cancer. ANGPTL4, angiopoietin-like 4; DFS, disease-free survival; OS, overall survival.

Article Snippet: Non-specific binding sites were blocked by incubation with 10% normal goat serum (cat. no. ab7481; Abcam) at room temperature for 20 min. Tissue sections were then incubated with a primary ANGPTL4 polyclonal antibody (dilution, 1:100; cat. no. A01147; Boster Biological Technology) at 37°C for 2 h. All sections were subsequently incubated using the Dako REALTM EnVisionTM Detection System (cat. no. K5007; Dako; Agilent Technologies, Inc.) containing biotinylated anti-rabbit secondary antibodies (dilution, 1:100) for 20 min at 37°C, and peroxidase-labelled streptavidin for 20 min at room temperature (dilution, 1:100).

Techniques: Expressing

Journal: Oncology Letters

Article Title: ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer

doi: 10.3892/ol.2020.11768

Figure Lengend Snippet: Cox proportional hazards regression analysis for DFS and OS.

Article Snippet: Non-specific binding sites were blocked by incubation with 10% normal goat serum (cat. no. ab7481; Abcam) at room temperature for 20 min. Tissue sections were then incubated with a primary ANGPTL4 polyclonal antibody (dilution, 1:100; cat. no. A01147; Boster Biological Technology) at 37°C for 2 h. All sections were subsequently incubated using the Dako REALTM EnVisionTM Detection System (cat. no. K5007; Dako; Agilent Technologies, Inc.) containing biotinylated anti-rabbit secondary antibodies (dilution, 1:100) for 20 min at 37°C, and peroxidase-labelled streptavidin for 20 min at room temperature (dilution, 1:100).

Techniques: